Discover
CTNM
Contineum Therapeutics, Inc.
15.24
2 x 11.59
2 x 19.57
bid
ask
-
1.15
7.02%
2 @ 04:00 PM
15.23 -0.01 (0.07%)
| Ytd | 33.33% | |
| 1y | 295.84% |
15.14
day range
16.39
3.72
52 week range
16.91
| Open | 16.37 | Prev Close | 16.39 | Low | 15.14 | High | 16.39 | Mkt Cap | 569.77M |
| Vol | 313.50K | Avg Vol | 302.67K | EPS | -1.94 | P/E | N/A | Forward P/E | -7.68 |
| Beta | N/A | Short Ratio | 13.66 | Inst. Own | 72.39% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 13.14 | 200-d Avg | 12.59 | 1yr Est | 29.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2025-02-05 | 2024-12 | -0.44 | N/A | N/A | N/A |
| 2024-11-06 | 2024-09 | -0.41 | -0.4 | 0.01 | 2.44% |
| 2024-08-13 | 2024-06 | -0.37 | N/A | N/A | N/A |
| 2024-08-13 | 2024-06 | -0.37 | -0.39 | -0.02 | -5.41% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-11-07 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-10-22 | Baird | Upgrade | Outperform | |
| 2024-08-14 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-04-30 | RBC Capital | Upgrade | Outperform | |
| 2024-04-30 | Stifel | Upgrade | Buy | |
| 2024-04-30 | Morgan Stanley | Upgrade | Overweight |
Profile
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-08-12 | HUHN STEPHEN L | Officer | 12.80K | Conversion of Exercise of derivative security |
| 2024-11-24 | LORRAIN DANIEL S. PH.D. | Officer | 172.46K | Sale |
| 2024-04-08 | VERSANT VENTURE CAPITAL VI, L.P. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Johnson & Johnson | 1.98M | 27.99M | 10.39% |
| 2024-09-29 | Suvretta Capital Management, LLC | 1.72M | 24.32M | 9.03% |
| 2024-09-29 | Perceptive Advisors Llc | 1.52M | 21.45M | 7.96% |
| 2024-09-29 | Franklin Resources, Inc. | 1.45M | 20.47M | 7.60% |
| 2024-09-29 | Versant Venture Management, LLC | 918.16K | 12.98M | 4.82% |
| 2024-09-29 | Sectoral Asset Management, Inc. | 800.89K | 11.32M | 4.20% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-07-30 | Franklin Strategic Series-Franklin Biotechnology Discove | 512.03K | 7.24M | 2.69% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 299.58K | 4.24M | 1.57% |
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 264.80K | 3.74M | 1.39% |
| 2024-10-30 | Fidelity Select Portfolios - Health Care | 200.00K | 2.83M | 1.05% |
| 2024-10-30 | iShares Russell 2000 ETF | 142.87K | 2.02M | 0.75% |
| 2024-10-30 | Fidelity Advisor Health Care Fund | 128.00K | 1.81M | 0.67% |